(wasn't planning to post this one, but given @seedy19tron just proposed to short $IOVA here because of $REPL, i thought i would add to the discussion. In addition to reasons mentioned here, $IOVA is no longer just a 2L+ melanoma story anymore, a positive data drop on NSCLC Q4